Search
Now showing items 1-4 of 4
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.
(MDPI, 2021-10-09)
Acute myeloid leukemia (AML) is a highly heterogeneous malignancy characterized by the clonal expansion of myeloid stem and progenitor cells in the bone marrow, peripheral blood, and other tissues. AML results from the ...
A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
(MDPI AG, 2021-10-21)
<jats:p>Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms against currently available drugs helps to ...
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis
(American Society of Hematology, 2022-02-03)
<jats:title>Abstract</jats:title>
<jats:p>The chronic phase of chronic myeloid leukemia (CP-CML) is characterized by the excessive production of maturating myeloid cells. As CML stem/progenitor cells (LSPCs) ...
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
(MDPI, 2021-09-28)
As the first FDA-approved tyrosine kinase inhibitor for treatment of patients with myelofibrosis (MF), ruxolitinib improves clinical symptoms but does not lead to eradication of the disease or significant reduction of the ...